GSK plans to invest $30 billion on research, development and supply chain infrastructure in the U.S. over the next five years.
The plan includes $1.2 billion for new manufacturing facilities and digital technologies, including a new biologics plant in Upper Merion, Pa., according to a Sept. 17 news release from the devicemaker.
Other investments will expand into drug substance manufacturing, device and auto injector production and AI capabilities at sites in Pennsylvania, Maryland, North Carolina and Montana.
The company also said the U.S. will be its largest base for clinical trials over the next five years, according to the release.
